US Stock MarketDetailed Quotes
ANIX Anixa Biosciences
- 3.100
- +0.010+0.32%
Close Aug 14 16:00 ET
- 3.280
- +0.180+5.81%
Post 16:20 ET
99.22MMarket Cap-8378P/E (TTM)
3.210High3.080Low101.72KVolume3.100Open3.090Pre Close317.83KTurnover0.34%Turnover RatioLossP/E (Static)32.01MShares5.13052wk High4.20P/B94.23MFloat Cap2.14552wk Low--Dividend TTM30.40MShs Float8.950Historical High--Div YieldTTM4.21%Amplitude0.056Historical Low3.124Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Anixa Biosciences Stock Forum
Anixa Biosciences Inc. (NASDAQ: ANIX) recently announced a milestone in its collaborative efforts with Moffitt Cancer Center. The U.S. Food and Drug Administration (FDA) has granted approval for an individual patient Investigational New Drug Application (IND), allowing the administration of a second dose of its CAR-T therapy fo...
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent application on breast cancer vaccine technology.
This extends the patent protection to Japan, in addition to existing U.S. and European patents.
Anixa is the exclusive worldwide licensee of this technology.
The vacci...
Anixa Biosciences Announces $5 Million Share Repurchase Program
On Monday, H.C. Wainwright & Co. adjusted its outlook on Anixa Biosciences (NASDAQ: ANIX) shares, reducing the 12-month price target to $7.00 from the previous $12.00 while maintaining a Buy rating. This adjustment is based on a recent financial report and a new partnership focused on cancer vaccine development. $Anixa Biosciences (ANIX.US)$
https://stockregion.app/p/prominent-investment-bank-maintains
NEWS
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targe...
NEWS
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
No comment yet